ORIGINAL RESEARCH ARTICLE ORIGINAL RESEARCH ARTICLE BACKGROUND: Most arteriovenous malformations (AVMs) are localized and occur sporadically. However, they also can be multifocal in autosomaldominant disorders, such as hereditary hemorrhagic telangiectasia and capillary malformation (CM)-AVM. Previously, we identified RASA1 mutations in 50% of patients with CM-AVM. Herein we studied non-RASA1 patients to further elucidate the pathogenicity of CMs and AVMs.
F
ast-flow lesions are characterized by direct communications between arteries and veins without an intervening normal capillary bed. In arteriovenous malformations (AVMs), the arterial blood is shunted from the feeding arteries into the draining veins by a bundle of abnormal vessels called the nidus. These lesions are usually congenital. Arteriovenous fistula is another variant, in which communication between an artery and vein is direct, often caused by trauma. Multiple micro-arteriovenous fistula are seen in Parkes Weber syndrome in association with soft tissue and skeletal hypertrophy of the affected limb (OMIM 608355). 1 AVMs can occur anywhere in the body; the central nervous system is the most common location. Symptoms depend on the site and age of the patient (eg, fetal hydrops, cardiac failure, epilepsy, and focal neurological deficit). 2 Progressive vascular dilation potentially leads to rupture and hemorrhage. 3 AVMs are 1 of the most difficult vascular anomalies to treat and are associated with high morbidity and mortality.
2,4,5 They are highly dynamic, with features of invasive growth, aggravation after incomplete resection, and regrowth even after clinically complete surgical removal. 6 AVMs can occur as an isolated feature or as part of a syndrome; the most common are hereditary hemorrhagic telangiectasia (HHT) and capillary malformation (CM)-AVM. [7] [8] [9] [10] HHT or Osler-Weber-Rendu syndrome (MIM187300) is a well-known autosomal-dominant, genetically heterogeneous disorder characterized by AVMs, typically in the liver and lung, in association with cutaneous and mucosal telangiectasias. CM-AVM (MIM608354) is an autosomal-dominant disorder with high penetrance and variable expressivity. 8 These patients have small multifocal cutaneous CMs. [9] [10] [11] AVMs are seen in ≈30% of the patients and are typically located in the brain, spinal cord, face, neck, or extremities. 9, 10, 12 Parkes Weber syndrome is included in this disorder. 10 Patients with CM-AVM do not have frequent epistaxis, the hallmark of HHT. 3, 7, 12 About 50% of patients with CM-AVM have heterozygous loss-of-function mutations in RASA1. 9, 10 This gene encodes the cytoplasmic P120RASGAP protein, a negative regulator of the RAS signal transduction pathway that enhances the weak intrinsic GTPase activity of normal RAS p21. 13 P120RASGAP plays an important role in vascular development during murine embryogenesis. 13, 14 We studied several families that have phenotypic CM-AVM but without an RASA1 mutation. Our hypothesis was that additional genes might be involved; we used linkage and whole-exome sequencing to further unravel the pathogenetic cause of this disorder.
METHODS

Recruitment of Patients
From our database of patients with vascular malformations collected in our long-active research project, we culled 365 index individuals. Inclusion criteria were sporadic or familial CMs associated or not with fast-flow vascular malformations. All the participants or their legal guardians gave informed consent for the participation in the study. The ethnicity of the patients with an identified mutation (n=54) varied: White, 42; Hispanic, 7; North African, 3; Japanese, 1; and Chinese, 1. The research protocol was approved by the ethical committee of the medical faculty at Université catholique de Louvain, Brussels, Belgium.
Linkage Analysis
Molecular karyotyping was performed in all samples with Affymetrix Human Mapping 250K NspI according to the manufacturer's instructions (see online-only Data Supplement). Genome-wide parametric multipoint linkage was performed using Merlin program12 in a large family with CM-AVM that did not have a RASA1 point mutation or genomic rearrangement (CM-13-HO; online-only Data Supplement Figure I ). The parametric analyses were run under an autosomal-dominant model, assuming a penetrance of 90% and 1% phenocopy rate. Haplotype reconstruction was used to exclude RASA1 and confirm segregation of the chromosome 7 locus with the CM-AVM phenotype in this family.
Clinical Perspective
What Is New?
• Identification of a second type of capillary malformation-arteriovenous malformation (CM-AVM), named CM-AVM2.
• CM-AVM2 is characterized by intra-and extracranial AVMs, multifocal CMs, and telangiectasias.
• CM-AVM2 mimics RASA1-mutated CM-AVM1 but also hereditary hemorrhagic telangiectasia (HHT).
• Prevalence of CM-AVM1/2 is similar to that of HHT.
• CM-AVM2 is inherited as an autosomal-dominant disorder.
• CM-AVM2 is caused by loss-of-function mutations in EPHB4.
• AVMs are caused by dysregulation of EPHB4-p120RASGAP (RASA1) interaction and downstream RAS-MAPK signaling.
What Are the Clinical Implications?
• Patients with multifocal CMs need to be screened for an inherited RASA1 mutation as well as EPHB4.
• Presence of telangiectasias may cause confusion with HHT.
• Screening of EPHB4 in HHT patients without a mutation in 1 of the 4 HHT genes and in patients with hereditary benign telangiectasia is to be considered to improve diagnostics.
• Risk for an intracentral system fast-flow lesion is lower than in CM-AVM1, but follow-up is needed.
• Inhibitors of EPHB4-p120RASGAP downstream signaling effectors, such as RAS and ERK, should be evaluated as possible molecular therapies for the management of AVM and CM.
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High-Throughput Sequencing
Genomic DNA for 1 affected CM-13-HO family member and 10 patients from 8 additional families were used for whole-exome sequencing. Exons were captured with Agilent SureSelectXT Human All Exon kit and sequenced with an Illumina HiSeq2000. We designed a custom AmpliSeq panel to sequence all exons and exon-intron boundaries of RASA1 and EPHB4 using the Ion PGM Sequencer. Called variants were annotated, filtered, and visualized using Highlander, an inhouse bioinformatics framework (Helaers R. et al, unpublished data, 2017). Our sequencing methods and variant filtering procedures are described in the online-only Data Supplement.
Effect of Nonsynonymous Variants on Ephb4 Function
Disease-causing variants were introduced in EGFP-EPHB4 cDNA by site-directed mutagenesis and transiently expressed in COS-7 cells. Stability of EPHB4 was accessed by Western blotting in cells treated or not with lysosome (Chloroquine) or proteasome inhibitors (MG132). Subcellular localization of EGFP-EPHB4 was evaluated by fluorescence imaging.
Statistical Analysis
To distinguish pathogenic mutations from background polymorphisms, we evaluated the distribution of rare nonsynonymous variants (NSVs) within the 2 genes, EPHB4 and RASA1. Only NSVs with maximum allele frequency <0.003 in 7 public databases (ExAC_af, 1000G_AF, ESP6500_AA_AF, ESP6500_ EA_AF, gonl_af, ARIC5606_AA_AF, and ARIC5606_EA_AF) were retained for analyses. NSVs were classified into tolerated or damaging on the basis of their aggregation score, as defined by Dong and coworkers. 15 These scores are based on 9 prediction algorithms (Sorting Intolerant From Tolerant, PolyPhen-2, GERP++, Mutation Taster, Mutation Assessor, Functional Analysis Through Hidden Markov Models, likelihood ratio test, SiPhy, PhyloP), the maximum frequency observed in the 1000 genomes database, and precomputed with logistic regression for 87 347 044 possible variants in the entire human exome. Frequencies of tolerated (aggregation score: 0-0.49) and damaging (aggregation score: 0.5-1) NSVs in RASA1 and EPHB4 genes were compared between our patient cohort and the control population on the basis of the largest public database ExAC 16 (60.706 unrelated whole exomes). Because our study group consisted mainly of Whites (79.6%), we excluded individuals of other ethnicities from this analysis. Enrichment was estimated by Pearson's χ 2 test: 2-sample test for equality of proportions with continuity correction (R-package v3.1.2).
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RESULTS
Identification of EPHB4 as the Mutated Gene
The genome-wide linkage analysis conducted with CM-13-HO family (online-only Data Supplement Figure IA Table I ). Subsequent targeted gene sequencing identified 47 distinct mutations in 54 index patients out of 365 sequenced: 9 were nonsense, 11 caused a frame shift, and 7 altered a consensus splice site. These 27 mutations suggested loss-of-function of EPHB4. Twenty variants led to amino acid substitutions predicted to alter protein function ( Figure 1 and Table 1 ). The mutations cosegregated with the phenotype in each family (onlineonly Data Supplement Figure II) . A splicing defect was confirmed in mRNA for 2 variants in subjects for whom lymphoblasts were available. Moreover, the frequency of rare damaging NSVs was significantly different between our study group and the large Exome Aggregation Consortium dataset (P<0.0001; online-only Data Supplement Figure III ). This was not seen for RASA1, mutations known to be STOP gains, Indels, or splice-site changes. The data fulfill all the criteria set up by MacArthur and colleagues 18 with regard to reporting on causality of sequence variants in newly identified genes. 18 The identified mutations are scattered along EPHB4 ( Figure 1 ). As the most 5-prime premature STOP codon appears at amino acid position 12, there is a low likelihood for neomorphic or dominant-negative function. There was no genotype-phenotype correlation according to position or type of mutation. Thus, all mutations should lead to haploinsufficiency. In 1 family, the c.345_347delCTA mutation deleted a tyrosine-(115) in the EphrinB2-binding domain, suggesting that this interaction may be particularly important for EPHB4-EphrinB2 signaling ( Figure 1) . Further evidence is a study of crystal structure of the ligand-binding domain of EPHB4 in complex with the extracellular domain of ephrinB2. 19 Yet several missense mutations (n=9/20) clustered within the catalytic domain of EPHB4, encoded by exons 14 and 15. We expressed 4 of them (p.E664K, p.C845R, p.R838W, and p.R864W) and detected a low level of mutant forms compared with the wild type ( Figure 2A ). Inhibition of endosome-lysosome acidification stabilized EPHB4 expression, bringing it close to wild-type levels, whereas inhibition of proteasomal system had a weak effect (Figure 2A) . The same effect was observed when the 2 treatments were combined with protein synthesis inhibitors (data not shown). The typical membranous staining of EPHB4 ( Figure 2A ) was not seen with mutant forms by immunofluorescence. Fluorescent vesicular inclusions without EPHB4 are detected only in mutant ( Figure 2B through 2F). In summary, these findings underscore that the mutations induce loss of function of EPHB4.
Identification of Mutations in EPHB4 Allowed Clinical Characterization of a New Entity: CM-AVM2
We analyzed clinical data from the 110 individuals (54 index patients and 56 relatives) found to have an EPHB4 mutation. Penetrance was high: 93% (n=102). Isolated multifocal CMs were identified in 34 families (63%). In the remaining 19 families (35%), ≥1 individual had an AVM in addition to CMs (Table 1 ). All affected subjects (n=102) had pink-to-red cutaneous CMs, usually multifocal; 10 patients had only 1 CM. About 25% of the CMs had a surrounding white halo believed to be caused by micro-AV shunting as detected by to-fro murmur with a hand-held Doppler instrument (Figure 3 ). CMs were either present at birth or appeared later during childhood or adolescence and were localized on the extremities, trunk, or head and neck. Size varied from pinpoint to large lesions, up to 15 cm in diameter; the borders were usually geographic. The stains were homogenous or telangiectatic, sometimes with a pale central zone. Bier spots were noted in 13 individuals (12%), and 16 (15%) had telangiectasias, especially on upper thorax and lips or periorally. Only a few patients had recurrent epistaxis.
Fast-flow lesions were present in 20 individuals (18%): arteriovenous fistulae (n=1), AVM (n=12), and Parkes Weber syndrome (n=8) (Figure 3) . Three lesions were located in the central nervous system: vein of Galen aneurysmal malformations (n=2) and intraspinal arteriovenous fistula (n=1). One additional vein of Galen aneurysmal malformation was identified in a fetus whose father carried an EPHB4 mutation, but fetal DNA was not available for analysis. The other AVMs were located in the face (n=8) and the extremities (n=1). One patient had 2 AVMs. The eight Parkes Weber lesions were located in the right arm (n=2), left arm (n=2), right leg (n=3), and left leg (n=1) ( Table 1) .
DISCUSSION
In this study, we identified EPHB4 as a second gene that is mutated in patients with CM-AVM. We propose to name this entity CM-AVM2 to differentiate it from CM-AVM1 caused by RASA1 mutations. These vascular disorders have similar characteristics but also differences, which are important for differential diagnosis. Both are characterized by multifocal CMs and increased risk for fast-flow vascular malformations. The CMs are usually small with a haphazard distribution. Bier spots are observed in both conditions but are more frequent in CM-AVM2. Moreover, the large CMs in CM-AVM2 can have a pale central region. Telangiectasias, especially obvious on the lips but also in the perioral region and the upper thorax, are seen in CM-AVM2 but not in CM-AVM1. Fast-flow vascular malformations occur in CM-AVM2 and CM-AVM1. However, the overall risk is somewhat lower in CM-AVM2 (18% versus 31%). The frequency of Parkes Weber syndrome and cervico-facial AVM is the same between the 2 entities: 7%. 9, 10 In contrast, AVMs in the central nervous system were found in 3% of patients with CM-AVM2, compared with 10% of patients with CM-AVM1. 9, 10, 12 It is important to note that the 2 intracranial AVMs diagnosed in CM-AVM2 were vein of Galen aneurysmal malformations; another vein of Galen anomaly was diagnosed in utero. Thus, EPHB4 is a supplementary gene to be considered in patients with this dangerous intracranial fast-flow lesion, often first detected prenatally.
Telangiectasias are a major feature of both HHT and hereditary benign telangiectasia. They can cause confusion with CM-AVM2. HHT is a well-known autosomaldominant, genetically heterogeneous disorder with 4 causative genes identified and at least 2 other loci awaiting elucidation. 7, [20] [21] [22] Hereditary benign telangiectasia is a rare autosomal-dominant disorder of unknown etiology and characterized by widespread cutaneous telangiectasias. In contrast to HHT, these patients have neither epistaxis nor fast-flow vascular malformations. 20, [23] [24] [25] The concurrence of CMs with telangiectasias in CM-AVM2 is a major clinical clue to differentiate it from HHT and hereditary benign telangiectasia. In addition, the extra central nervous system fast-flow vascular malformations are different in CM-AVM2 from those in HHT. CM-AVM2 is associated with cutaneous, subcutaneous, muscular, and bony AVMs in the face and neck or extremities and Parkes Weber syndrome, whereas pulmonary and hepatic AVMs occur in HHT.
Because not all patients with HHT have pulmonary or hepatic AVMs, sequencing EPHB4 in those without a mutation in 1 of the 4 HHT genes is indicated. It would also be interesting to test EPHB4 in patients with hereditary benign telangiectasia because all the features in this disorder are observed in patients with CM-AVM2.
The prevalence of HHT is reported to be 1 in 5000. 26 The Exome Aggregation Consortium dataset includes 10 loss-of-function mutations (premature STOP codons or strong splice-site mutations) in 60 706 subjects, a prevalence of 1 in 6000. Similar mutations are present 3 times in RASA1 and 5 times in EPHB4. Thus, prevalence estimates are 1 in 20 000 and 1 in 12 000, respectively. This calculation ignores all pathogenic amino acid substitutions. Overall, the prevalence of CM-AVM1/2 is similar to that of HHT1/2/3, and CM-AVM subtypes are strongly underdiagnosed. Mutations in EPHB4 were identified in 54 families. Most mutations were private to each affected family AVM indicates arteriovenous malformations; CM, capillary malformation; ExAC, Exome Aggregation Consortium; HGVS, annotation based on Human Genome Variation Society; VGAM, vein of Galen aneurysmal malformation; and VGAM/VGAM, 2 affected individuals in the same family. Consensus prediction is a functional prediction retrieved from dbNSFP4.1 (damaging in Sorting Intolerant From Tolerant, deleterious in likelihood ratio test, high or medium in mutation assessor, damaging in Fathmm, disease-causing in Mutation Taster, and a score >0.5 in Polyphen2).
Consensus prediction column gives the number of different algorithms that suggest a variant to be damaging. The maximum is 6 for missense variants because 6 different algorithms are used (Sorting Intolerant From Tolerant, likelihood ratio test, mutation assessor, FATHMM, Mutation Taster, and Polyphen2). In addition, if the variant affects splicing (evaluated by 2 distinct algorithms: ada and rf), +1 or +2 is added. Furthermore, to better distinguish variants with high potential for deleterious effects, +10 is added for variants that cause a loss of a start or stop codon or insertion or deletion of a codon with or without codon change; +20 is added for variants in splice-site regions; +30 is added for variants in consensus splice sites and for small exon deletions; and +40 is added for variants causing a frame shift or appearance of a premature STOP codon.
*Nonsense mutation position in protein.
†Confirmed sporadic case. ‡DNA was not available from other affected family members. except for 5 mutations, which occurred in 2 families, and 1 mutation, which occurred in 3 families. The mutations are located throughout the gene; we found no genotype-phenotype correlations. The localized nature and multifocality of lesions in CM-AVM2 can be explained by the need for a somatic second hit for complete cellular abolishment of EPHB4 function. This 2-hit phenomenon has been shown for other heredi- tary multifocal vascular malformations, such as CM-AVM1, glomuvenous malformations (OMIM 138000), and cutaneomucosal venous malformations (OMIM 600195). 10, [27] [28] [29] The inherited mutation can be considered a predisposing event, whereas additional genetic alterations disturb cellular function. No mutation was identified in 311 index patients. This negative finding was not unexpected taking into consideration the heterogeneity of our cohort, which includes patients with sporadic or familial CMs with and without a fast-flow vascular malformation. Moreover, regulatory regions were not analyzed.
The mechanism leading to CMs and AVMs in CM-AVM2 is likely a loss of function of EPHB4. The majority of the mutations generate a premature stop codon, frame-shift, or splice-site alteration (57%), leading to nonsense-mediated mRNA decay or an unstable and truncated protein. Moreover, our functional studies on several missense mutations, enriched in the catalytic domain of EPHB4, have shown reduced expression of mutant protein caused by lysosomal degradation. Because other inherited multifocal vascular anomalies have somatic second hits, it is likely that the endothelial cells that drive formation of the lesions in CM-AVM2 are completely devoid of EPHB4 function. Unfortunately, we did not have tissue available to study this theory.
EPHB4 is a transmembrane receptor that is preferentially expressed in venous endothelial cells during vascular development. 30, 31 Its ligand, EphrinB2, is also a transmembrane protein, which is expressed in arterial endothelial cells. 32 This bidirectional signaling system, in concert with Notch signaling, is a major controller of arterial-venous differentiation, especially by the forward signaling of EPHB4. 33, 34 Coordinated activation of the 2 proteins is essential for the establishment of venous and arterial endothelial identity and corresponding vessel formation (Figure 4) . 33, 34 EphB4-/ -and ephrin-B2-/ -mice 30, 35 die at embryonic day 10.5 as a consequence of defects in peripheral angiogenesis, establishment of arteriovenous boundaries, and vascular remodeling. EPHB4 signals by RAS-MAPK-ERK1/2 and PI3K-AKTmTORC1 pathways. 36 In zebrafish, inhibition of EPHB4 or p120RasGap causes similar vascular defects. 37 Moreover, EPHB4 with mutated conserved juxtamembrane tyrosine residues abrogates the interaction with p120RASGAP, demonstrating that it is a pivotal effector of EPHB4 signaling. 38 The phenotypic similarity of CM-AVM1 and CM-AVM2 underscores this functional link and incriminates dysregulation in the EPHB4 signaling pathway as the cause of CM and AVM. Consequently, RAS and its downstream effectors, RAS-MAPK-ERK1/2 and PI3K-AKT-mTORC1, are constitutively activated (Figure 4) . ERK activation was observed in tissue samples from patients with RASA1 mutation. 37 Moreover, single somatic activating GNAQ/GNA11 mutations in sporadic CMs also activate these pathways. 39, 40 Thus, sporadic AVMs are likely caused by somatic activating mutations in key molecule(s) of this signaling pathway as recently reported for 16 out of 25 patients with an extracranial sporadic AVM. 41 The annual risk of hemorrhage associated with brain AVMs is ≈2% per year. 42 The ARUBA (Randomised Trial of Unruptured Brain Arteriovenous Malformations) concluded that medical management is superior to endovascular interventional therapy alone for the prevention of death and stroke. 42 Extracranial AVMs present an equal therapeutic dilemma, with early complete surgical resection with and without embolization being the only hope for long-term control. 43 Inhibitors of EPHB4-p120RASGAP downstream signaling effectors, such as RAS and ERK, should be evaluated as possible therapy for AVM and CM.
In conclusion, we identified a hitherto unrecognized clinical entity, similar in clinical presentation to CM-AVM1, and thus named CM-AVM2. Cutaneous CMs are highly penetrant and associated with AVMs. Telangiectasias and epistaxis also occur, placing this novel disorder phenotypically between CM-AVM1 and HHT. The distribution of AVMs is more similar to CM-AVM1. CM-AVM2 is caused by loss-of-function mutations in EPHB4, whereas CM-AVM1 is due to loss of function of p120RASGAP. The latter has been demonstrated to be a direct effector of EPHB4. Our data highlight the pathogenetic importance of this interaction and indicts the EPHB4-RAS-ERK signaling pathway as a major cause for CMs and AVMs. Modulating activity of the EPHB4-RAS-ERK pathway would be a novel therapeutic strategy.
